HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gottlieb Becomes FDA Commissioner With Immediate Issues Pending

This article was originally published in The Rose Sheet

Executive Summary

Confirmation comes with fewest votes of any recent commissioner as FDA faces pressing budget, user-fee and other issues. The Personal Care Products Council welcomed Gottlieb to the post and took the occasion to plug cosmetics industry virtues at a time when legislation is under consideration to update regulations.

You may also be interested in...



FDA To Curtail Cosmetics Safety Work Under FY 2018 Budget Constraints

President Trump's budget proposal for fiscal 2018 calls for "targeted reductions to the Food Safety program, including reducing staff levels through attrition." In its justification to congressional appropriators, FDA says it will reduce funding for cosmetics safety work in order to focus on top priorities in the broad foods area.

Ostroff: Administration Coming Up To Speed On Planned FDA Guidances

There’s been a dearth of guidances from US FDA since Donald Trump's inauguration, but the acting FDA commissioner says that simply reflects the new administration catching up on what's in the pipeline. In a speech at FDLI's annual meeting, Stephen Ostroff struck a positive tone.

FDA Gains Budget Increase In FY 2017 … And Not Through Fees

Omnibus legislation to fund the federal government for FY 2017 includes an increase in non-user fee funds, which should please stakeholders.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109243

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel